{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:17:59Z","timestamp":1791285479236,"version":"4.1.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Diabetic nephropathy is associated with endothelial dysfunction and oxidative stress, in which the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway is impaired. We hypothesize that sGC stimulator Compound 1 can enhance NO signaling, reduce proteinuria in a diabetic nephropathy preclinical model with diminished NO bioavailability and increased oxidized sGC. Therefore, we evaluated the effect of sGC stimulator Compound 1 on the renal effect in obese ZSF1 (ZSF1 OB) rats.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>The sGC stimulator Compound 1, the standard of care agent Enalapril, and a combination of Compound 1 and Enalapril were administered chronically to obese ZSF1 rats for 6 months. Mean arterial pressure, heart rate, creatinine clearance for glomerular filtration rate (eGFR), urinary protein excretion to creatinine ratio (UPCR), and urinary albumin excretion ratio (UACR) were determined during the study. The histopathology of glomerular and interstitial lesions was assessed at the completion of the study.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>While both Compound 1 and Enalapril significantly reduced blood pressure, the combination of Compound 1 and Enalapril normalized blood pressure levels. Compound 1 improved eGFR and reduced UPCR and UACR. A combination of Enalapril and Compound 1 resulted in a marked reduction in UPCR and UACR and improved GFR.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The sGC stimulator Compound 1 as a monotherapy slowed renal disease progression, and a combination of the sGC stimulator with Enalapril provided greater renal protection in a rodent model of diabetic nephropathy.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0261000","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T18:37:34Z","timestamp":1643308654000},"page":"e0261000","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9271-1285","authenticated-orcid":true,"given":"Lufei","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Blumenschein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Grein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayathri","family":"Swaminath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"6","key":"pone.0261000.ref001","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms19061712","article-title":"The Impact of the Nitric Oxide (NO)\/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective.","volume":"19","author":"SM Krishnan","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"pone.0261000.ref002","doi-asserted-by":"crossref","first-page":"e00354","DOI":"10.1002\/prp2.354","article-title":"An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model.","volume":"5","author":"X Zhou","year":"2017","journal-title":"Pharma Res Per"},{"key":"pone.0261000.ref003","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2014.12.014","article-title":"Renal effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence","volume":"21","author":"JP Stasch","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"pone.0261000.ref004","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Renal Pathology Society, Pathologic classification of diabetic nephropathy","volume":"21","author":"TW Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"pone.0261000.ref005","first-page":"Svii, S1","article-title":"US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States.","volume":"66","author":"R Saran","year":"2015","journal-title":"Am J Kidney Disease."},{"key":"pone.0261000.ref006","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMsa063904","article-title":"Nitric oxide and cyclic GMP in cell signaling and drug development","volume":"355","author":"F. Murad","year":"2006","journal-title":"N Engl J Med"},{"key":"pone.0261000.ref007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cbpb.2005.04.022","article-title":"Nitric oxide and mitochondrial biogenesis: a key to long-term regulation of cellular metabolism","volume":"142","author":"E Clementi","year":"2005","journal-title":"Comp Biochem Physiol A Mol Integr Physiol"},{"key":"pone.0261000.ref008","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/cvr\/cvn098","article-title":"Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha","volume":"79","author":"R Ventura-Clapier","year":"2008","journal-title":"Cardiovasc Res"},{"key":"pone.0261000.ref009","doi-asserted-by":"crossref","first-page":"29640","DOI":"10.1074\/jbc.M302143200","article-title":"cGMP-dependent protein kinase type II regulates basal level of aldosterone production by zona glomerulosa cells without increasing expression of the steroidogenic acute regulatory protein gene","volume":"278","author":"S Gambaryan","year":"2003","journal-title":"J Biol Chem"},{"key":"pone.0261000.ref010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-540-68964-5_2","article-title":"Biochemistry of soluble guanylate cyclase","volume":"191","author":"ER Derbyshire","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"pone.0261000.ref011","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-biochem-050410-100030","article-title":"Structure and regulation of soluble guanylate cyclase","volume":"81","author":"ER Derbyshire","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"pone.0261000.ref012","doi-asserted-by":"crossref","first-page":"R913","DOI":"10.1152\/ajpregu.00250.2005","article-title":"Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension","volume":"289","author":"CS Wilcox","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"pone.0261000.ref013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.RES.87.10.840","article-title":"Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress","volume":"87","author":"H Cai","year":"2000","journal-title":"Circ Res"},{"key":"pone.0261000.ref014","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.semnephrol.2004.04.007","article-title":"Nitric oxide, oxidative stress, and progression of chronic renal failure.","volume":"24","author":"PS Modlinger","year":"2004","journal-title":"Semin Nephrol."},{"key":"pone.0261000.ref015","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00424.2007","article-title":"Nitric oxide deficiency in chronic kidney disease","volume":"294","author":"C. Baylis","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"pone.0261000.ref016","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1871529X14666140401110841","article-title":"Renal endothelial dysfunction in diabetic nephropathy.","volume":"14","author":"H Cheng","year":"2014","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"pone.0261000.ref017","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nrendo.2010.212","article-title":"Oxidative stress in early diabetic nephropathy: fueling the fire.","volume":"7","author":"DK Singh","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"pone.0261000.ref018","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.2174\/092986710793348581","article-title":"Oxidative stress in diabetic nephropathy","volume":"17","author":"N Kashihara","year":"2010","journal-title":"Curr Med Chem"},{"issue":"1","key":"pone.0261000.ref019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.","volume":"19","author":"SH Park","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"8","key":"pone.0261000.ref020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0192623318803278","article-title":"41-Week Study of Progressive Diabetic Nephropathy in the ZSF1 fa\/faCP Rat Model","volume":"46","author":"BL Homer","year":"2018","journal-title":"Toxicologic Pathology"},{"key":"pone.0261000.ref021","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"JP Stasch","year":"2011","journal-title":"Circulation"},{"key":"pone.0261000.ref022","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1523-1755.2005.00380.x","article-title":"Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis","volume":"68","author":"Y Wang","year":"2005","journal-title":"Kidney Int"},{"key":"pone.0261000.ref023","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/HJH.0b013e32833b558c","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models","volume":"28","author":"Y Sharkovska","year":"2010","journal-title":"J Hypertens"},{"key":"pone.0261000.ref024","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjp.0706792","article-title":"NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5\/6 nephrectomy","volume":"148","author":"P Kalk","year":"2006","journal-title":"Br J Pharmacol"},{"key":"pone.0261000.ref025","doi-asserted-by":"crossref","first-page":"e0145048","DOI":"10.1371\/journal.pone.0145048","article-title":"Chronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.","volume":"10","author":"LS Hoffmann","year":"2015","journal-title":"PLoS One."},{"key":"pone.0261000.ref026","doi-asserted-by":"crossref","first-page":"F685","DOI":"10.1152\/ajprenal.00280.2004","article-title":"Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis. American Journal of Physiology","volume":"288","author":"B Hohenstein","year":"2005","journal-title":"Renal Physiology"},{"issue":"210","key":"pone.0261000.ref027","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-11-0122","article-title":"Diabetic nephropathy and long-term treatment effects of rosiglitazone and Enalapril in obese ZSF1 rats","author":"VP Bilan","year":"2011","journal-title":"J Endocrinol"},{"key":"pone.0261000.ref028","author":"M Stolina","year":"2020","journal-title":"The evolving systemic biomarker milieu in obese ZSF1 rat model of human cardiometabolic syndrome: Characterization of the model and cardioprotective effect of GDF15"},{"key":"pone.0261000.ref029","first-page":"1","article-title":"Soluble guanylyl cyclase (sGC) activator effects in kidney pathophysiology.","volume":"17","author":"A Benardeau","year":"2019","journal-title":"J. of Trans Med"},{"key":"pone.0261000.ref030","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12933-015-0309-x","article-title":"The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus","volume":"14","author":"C M\u00e1ty\u00e1s","year":"2015","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"pone.0261000.ref031","doi-asserted-by":"crossref","first-page":"11218","DOI":"10.1038\/s41598-017-10125-3","article-title":"Cinaciguat ameliorates glomerular damage by reducing ERK1\/2 activity and TGF-\u00df expression in type-1 diabetic rats.","volume":"7","author":"S Czirok","year":"2017","journal-title":"Sci Rep."},{"issue":"8","key":"pone.0261000.ref032","doi-asserted-by":"crossref","first-page":"e42623","DOI":"10.1371\/journal.pone.0042623","article-title":"Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade","volume":"7","author":"IM Ott","year":"2012","journal-title":"PLoS One"},{"key":"pone.0261000.ref033","first-page":"29","volume-title":"Rat Models of the Metabolic Syndrome in Methods in Molecular Medicine 86, Renal Disease: Techniques and Protocols","author":"SP Tofovic","year":"2003"},{"key":"pone.0261000.ref034","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1681\/ASN.2006080895","article-title":"Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production","volume":"18","author":"S Prabhakar","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"pone.0261000.ref035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1527-3466.2007.00003.x","article-title":"Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41\u20132272 in cardiovascular disease.","volume":"25","author":"G Boerrigter","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"pone.0261000.ref036","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/jpet.115.230706","article-title":"A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat","volume":"356","author":"CM Boustany-Kari","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"pone.0261000.ref037","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.","volume":"38","author":"P Burkert","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"pone.0261000.ref038","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/cpt.10","article-title":"Soluble Guanylate Cyclase: A new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension","volume":"97","author":"AD Gupta","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0261000.ref039","first-page":"355","volume-title":"Soluble Guanylate Cyclase Stimulators and Activators.","author":"P Sandner","year":"2019"},{"issue":"5","key":"pone.0261000.ref040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000449324","article-title":"Longitudinal Changes in Measured Glomerular Filtration Rate, Renal Fibrosis and Biomarkers in a Rat Model of Type 2 Diabetic Nephropathy.","volume":"44","author":"Z Su","year":"2016","journal-title":"Am J Nephrol."},{"key":"pone.0261000.ref041","first-page":"290805","article-title":"Stimulators and Activators of soluble guanylate cyclase: Review and potential therapeutic indications.","volume":"2012","author":"B Nossman","year":"2012","journal-title":"Crit Care Res Prac."},{"key":"pone.0261000.ref042","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1172\/JCI4044","article-title":"Role of cGMP-kinase II in the control of renin secretion and renin expression.","volume":"102","author":"C Wagner","year":"1998","journal-title":"J Clin Investig."},{"key":"pone.0261000.ref043","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1073\/pnas.95.8.4743","article-title":"Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3.","volume":"95","author":"A Kurtz","year":"1998","journal-title":"PNAS"},{"key":"pone.0261000.ref044","doi-asserted-by":"crossref","first-page":"F1376","DOI":"10.1152\/ajprenal.00209.2005","article-title":"cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3","volume":"290","author":"William Beierwaltes","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"pone.0261000.ref045","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fphar.2019.00800","volume":"10","author":"A Schramm","year":"2019","journal-title":"Front Pharmacol."},{"key":"pone.0261000.ref046","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2174\/1381612811319170009","article-title":"Angiotensin ll Blockade and Renal Protection.","volume":"19","author":"H Kobori","year":"2013","journal-title":"Curr Pharm Des."},{"issue":"3","key":"pone.0261000.ref047","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11906-010-0106-6","article-title":"Baroreflex stimulation in antihypertensive treatment.","volume":"12","author":"JG Taylor","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"pone.0261000.ref048","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNH.0b013e32835b36c1","article-title":"Renal microvascular dysfunction, hypertension and CKD progression","volume":"22","author":"AK Bidani","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"pone.0261000.ref049","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.RES.84.2.186","article-title":"Nitric oxide\/cAMP interactions in the control of rat renal vascular resistance","volume":"84","author":"P Sandner","year":"1999","journal-title":"Circ Res"},{"key":"pone.0261000.ref050","first-page":"F885","article-title":"Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney","volume":"268","author":"S Bachmann","year":"1995","journal-title":"Am J Physiol"},{"key":"pone.0261000.ref051","doi-asserted-by":"crossref","first-page":"H163","DOI":"10.1152\/ajpheart.1988.254.1.H163","article-title":"Vascular relaxation and cGMP in hypertension","volume":"254","author":"Y Otsuka","year":"1988","journal-title":"Am J Physiol. Heart Circ. Physiol"},{"issue":"12","key":"pone.0261000.ref052","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"BM Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0261000.ref053","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1172\/JCI7709","article-title":"Cystatin C deficiency in human atherosclerosis and aortic aneurysms","volume":"104","author":"GP Shi","year":"1999","journal-title":"J Clinical Investigation"},{"issue":"4","key":"pone.0261000.ref054","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/j.1523-1755.2004.00517.x","article-title":"Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement","volume":"65","author":"EL Knight","year":"2004","journal-title":"Kidney International"},{"issue":"2","key":"pone.0261000.ref055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/00365510510013523","article-title":"Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans","volume":"65","author":"P Sj\u00f6str\u00f6m","year":"2005","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"issue":"3","key":"pone.0261000.ref056","first-page":"1219","article-title":"Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology","volume":"11","author":"J Song","year":"2019","journal-title":"Am J Transl Res."},{"issue":"1\u20132","key":"pone.0261000.ref057","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11010-016-2700-7","article-title":"Kidney injury molecule-1 (KIM-1) mediates renal epithelial cell repair via ERK MAPK signaling pathway.","volume":"416","author":"Z Zhang","year":"2016","journal-title":"Mol Cell Biochem"},{"issue":"21","key":"pone.0261000.ref058","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1073\/pnas.1803945115","article-title":"Farnesoid X receptor is essential for the survival of renal medullary collecting duct cells under hypertonic stress. Oxidative Medicine and Cellular Longevity","volume":"115","author":"S Xu","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0261000.ref059","first-page":"88","article-title":"The Role of Nrf2-Mediated Pathway in Cardiac Remodeling and Heart Failure","volume":"97","author":"S Zhou","year":"2015","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T18:38:35Z","timestamp":1643308715000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261000"}},"subtitle":[],"editor":[{"given":"Michael","family":"Bader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261000","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}